FY2025 EPS Estimates for TG Therapeutics Cut by Analyst

TG Therapeutics, Inc. (NASDAQ:TGTX) – Analysts at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for TG Therapeutics in a research note issued to investors on Tuesday, May 6th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the biopharmaceutical company will post earnings of $0.58 per share for the year, down from their previous estimate of $1.08. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). The firm had revenue of $120.86 million during the quarter, compared to analysts’ expectations of $117.07 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm’s quarterly revenue was up 90.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.07) earnings per share.

A number of other research analysts have also commented on TGTX. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $40.80.

TG Therapeutics Stock Performance

Shares of NASDAQ:TGTX opened at $33.64 on Thursday. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The company has a 50-day moving average price of $38.90 and a 200-day moving average price of $33.56. The company has a market cap of $5.34 billion, a price-to-earnings ratio of -336.37 and a beta of 2.21. TG Therapeutics has a 12 month low of $15.16 and a 12 month high of $46.48.

Hedge Funds Weigh In On TG Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. CWM LLC raised its position in shares of TG Therapeutics by 16.2% in the 1st quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 290 shares during the last quarter. Arizona State Retirement System raised its holdings in TG Therapeutics by 0.9% in the fourth quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company’s stock worth $1,283,000 after buying an additional 364 shares during the last quarter. Blue Trust Inc. lifted its stake in shares of TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 371 shares in the last quarter. Golden State Wealth Management LLC raised its holdings in TG Therapeutics by 100.0% in the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 433 shares during the last quarter. Finally, Summit Investment Advisors Inc. lifted its position in TG Therapeutics by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company’s stock valued at $440,000 after acquiring an additional 463 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.